MoDE™ and TRAP™ Degraders Pipeline Innovation Engine Clinical Trials at Biohaven Publications Harness the body’s protein recycling machinery for rapid and selective removal of disease-causing proteins. Hear Leading Expert, Professor Jonathan Barratt, Ph.D., FRCP, discuss Gd-IgA1, the Current IgAN Treatment Landscape, and BHV-1400. MoDE and TRAP Degraders are administered via subcutaneous or IV injection bind to circulating disease-causing proteins and deliver them to ASGPRs on hepatocytes for internalization and degradation HEPATOCYTE
